[go: up one dir, main page]

PT1242060E - Tratamento da doenca metastatica - Google Patents

Tratamento da doenca metastatica

Info

Publication number
PT1242060E
PT1242060E PT00955687T PT00955687T PT1242060E PT 1242060 E PT1242060 E PT 1242060E PT 00955687 T PT00955687 T PT 00955687T PT 00955687 T PT00955687 T PT 00955687T PT 1242060 E PT1242060 E PT 1242060E
Authority
PT
Portugal
Prior art keywords
treatment
metastatic disease
compounds
metastatic
disease
Prior art date
Application number
PT00955687T
Other languages
English (en)
Inventor
Kinch Michael Scott
Katherine E Kilpatrick
Nicole D Zantek
Patrick W Hein
Original Assignee
Glaxo Group Ltd
Purdue Research Foundation
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22529456&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1242060(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd, Purdue Research Foundation, Univ North Carolina filed Critical Glaxo Group Ltd
Publication of PT1242060E publication Critical patent/PT1242060E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT00955687T 1999-08-17 2000-08-17 Tratamento da doenca metastatica PT1242060E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14925899P 1999-08-17 1999-08-17

Publications (1)

Publication Number Publication Date
PT1242060E true PT1242060E (pt) 2006-08-31

Family

ID=22529456

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00955687T PT1242060E (pt) 1999-08-17 2000-08-17 Tratamento da doenca metastatica

Country Status (10)

Country Link
EP (2) EP1242060B1 (pt)
JP (2) JP2003516930A (pt)
AT (1) ATE324877T1 (pt)
AU (1) AU6784400A (pt)
CA (1) CA2380888A1 (pt)
DE (1) DE60027768T2 (pt)
DK (1) DK1242060T3 (pt)
ES (1) ES2261230T3 (pt)
PT (1) PT1242060E (pt)
WO (1) WO2001012172A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
EA005823B1 (ru) 2000-03-31 2005-06-30 Пердью Рисерч Фаундейшн Способ лечения с использованием конъюгатов лиганд-иммуноген
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
JP2004523232A (ja) * 2001-01-23 2004-08-05 プリマゲン ホールディング ベー．フェー． 治療評価の手段と方法
EP1225233A3 (en) * 2001-01-23 2003-01-08 Amsterdam Support Diagnostics B.V. Means and methods for treatment evaluation
EP1298221A1 (en) * 2001-09-28 2003-04-02 PrimaGen Holding B.V. Means and methods for treatment evaluation
EP1434603B1 (en) * 2001-09-28 2009-12-16 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
JP2005535289A (ja) * 2002-02-15 2005-11-24 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １４１４分子、１４８１分子、１５５３分子、３４０２１分子、１７２０分子、１６８３分子、１５５２分子、１６８２分子、１６７５分子、１２８２５分子、９９５２分子、５８１６分子、１０００２分子、１６１１分子、１３７１分子、１４３２４分子、１２６分子、２７０分子、３１２分子、１６７分子、３２６分子、１８９２６分子、６７４７分子、１７９３分子、１７８４分子または２０４５分子を用いて、ａｉｄｓおよびｈｉｖ関連障害を処置するための方法および組成物
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
AU2003243228B2 (en) * 2002-05-10 2009-03-26 Medimmune, Llc EphA2 monoclonal antibodies and methods of use thereof
AU2003239585B2 (en) 2002-05-23 2009-06-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (LMW-PTP) as diagnostic and therapeutic target
AU2004210463B2 (en) * 2003-02-07 2009-07-16 Ludwig Institute For Cancer Research Limited Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis
AU2003900541A0 (en) * 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
CA2521594A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
CA2522082A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
EP2266628A3 (en) 2003-05-13 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Method of determining the susceptibility to bone meatastases by EPhA2 expression
WO2005016381A2 (en) * 2003-07-21 2005-02-24 Medimmune, Inc. Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah
JP4860477B2 (ja) * 2003-11-20 2012-01-25 メディミューン，エルエルシー ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
CA2567254C (en) 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
EP1784424A4 (en) 2004-08-16 2009-03-18 Medimmune Inc EPH RECEPTOR BINDING FC VARIANTS HAVING CELLULAR CELLULAR ACTIVITY DEPENDENT ANTIBODIES
US7569672B2 (en) 2005-02-04 2009-08-04 Raven Biotechnologies, Inc. Antibodies that bind to EphA2 and methods of use thereof
WO2007092299A2 (en) 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
ZA200900545B (en) * 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
WO2008033966A2 (en) 2006-09-12 2008-03-20 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
ES2746960T3 (es) 2006-09-12 2020-03-09 Alphavax Inc Partículas de replicón de alfavirus que codifican IL-12 como adyuvantes inmunológicos
WO2008058035A1 (en) 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
CN101848998B (zh) * 2007-08-30 2016-08-03 第一三共株式会社 抗epha2抗体
TW201116297A (en) 2009-10-02 2011-05-16 Sanofi Aventis Antibodies that specifically bind to the EphA2 receptor
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
WO2018034332A1 (ja) * 2016-08-19 2018-02-22 国立大学法人東京大学 ＥｐｈＡ２ Ｎ末端フラグメント抗体
WO2020028749A1 (en) 2018-08-03 2020-02-06 Uab Research Foundation Methods and compositions for alphavirus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2129454T3 (es) 1991-08-22 1999-06-16 Becton Dickinson Co Procedimientos y composiciones de tratamientos de cancer y pronostico de reacciones a los indicados tratamientos.
CA2103323A1 (en) * 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
IL142921A0 (en) * 1998-11-20 2002-04-21 Genentech Inc USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS

Also Published As

Publication number Publication date
EP1242060A4 (en) 2003-09-24
WO2001012172A1 (en) 2001-02-22
WO2001012172B1 (en) 2001-08-16
EP2289940A3 (en) 2011-09-21
JP2003516930A (ja) 2003-05-20
EP1242060B1 (en) 2006-05-03
AU6784400A (en) 2001-03-13
CA2380888A1 (en) 2001-02-22
DK1242060T3 (da) 2006-08-21
JP2007306938A (ja) 2007-11-29
DE60027768D1 (de) 2006-06-08
DE60027768T2 (de) 2007-04-05
EP2289940A2 (en) 2011-03-02
ATE324877T1 (de) 2006-06-15
ES2261230T3 (es) 2006-11-16
EP1242060A1 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
PT1242060E (pt) Tratamento da doenca metastatica
TR200200928T2 (tr) 2-pirazolin-5-on terkipleri
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
GB9903762D0 (en) Organic compounds
NO2010002I2 (no) Toceranibfosfat.
CA2367704A1 (en) Pyrazolobenzodiazepines as cdk2 inhibitors
BR0207378A (pt) Tratamento de câncer
UY26981A1 (es) Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona
BR0117063A (pt) Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
CY1106816T1 (el) 1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
NO20070951L (no) Inhibitorer av angiopoientinlignende-4-protein, kombinasjoner og deres anvendelse.
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
TR200200260T2 (tr) N-desmetilzopiklonlarının üretim ve kullanım yöntemleri
BR0316296A (pt) Compostos lapacone e seus métodos de uso
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
TR200201089T2 (tr) Dipiridamol veya mopidamolün fibrine bağlı mikrodolaşım bozukluklarının tedavisi
ATE406155T1 (de) Triptolid-prodrugs zur krebstherapie
HUP0104046A2 (hu) Adenovírus-közvetített génterápia
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina